Canada Markets close in 1 hr 45 mins

Ultimovacs ASA (ULTI.OL)

Oslo - Oslo Delayed Price. Currency in NOK
Add to watchlist
70.000.00 (0.00%)
At close: 04:25PM CEST
Full screen
Previous Close70.00
Open70.00
Bid70.00 x N/A
Ask70.30 x N/A
Day's Range69.30 - 71.00
52 Week Range60.50 - 170.20
Volume30,253
Avg. Volume27,724
Market Cap2.396B
Beta (5Y Monthly)1.31
PE Ratio (TTM)N/A
EPS (TTM)-4.32
Earnings DateFeb 17, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ultimovacs ASA: Mandatory notification of trade by primary insider

    Oslo, 30 June 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of NOK 69.50 per share. Following this transaction, Carlos de Sousa and closely related parties hold 18,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Secu

  • GlobeNewswire

    Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

    Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer

  • GlobeNewswire

    Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial

    30 patients treated with UV1/pembrolizumab24-month survival rate of 73%Promising survival data follows encouraging clinical response rates and good safety Oslo, 20 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today positive 2-year overall survival data in its ongoing phase I clinical study of the cancer vaccine UV1 in combination with pembrolizumab for the treatment of malignant melanoma. Across all 30 patients